Analgosedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU Patients

Ketamine is used to produce sedation and relieve pain to minimize discomfort while a breathing tube placed in trachea (windpipe) and a machine (ventilator) used in the ICU. Several publications have shown that a low-dose ketamine in combination to opioids has been used to relieve acute pain after surgery. Ketamine has a favorable characteristics including bronchodilation, increase in blood pressure, does not cause constipation , maintain respiratory reflexes (respiratory spontaneous responses) make it an especially viable alternative for patients with unstable respiratory and hemodynamic function. However, the majority of these trials are conducted in a surgical ICU setting, retrospective in nature or randomized controlled clinical trials focusing on comparison of ketamine to placebo or two study drugs (e.g. ketamine versus opioid), despite the fact that most ICU patients are sedated with a combination of drugs. Moreover, the majority of those trials has a limited focus on patient-centered outcomes, as the primary outcome.

The aim of this study is to assess weather ketamine can help to shorten the time of being in breathing tube and ventilator (duration of mechanical ventilation). This is a prospective, randomized, active controlled, open-label pilot study to assess the efficacy and safety of Analgo-sedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU patients (ATTAINMENT trial). The study hypothesis is that low dose ketamine infusion will reduce the duration of mechanical ventilation with an acceptable safety profile compared to standard of care. The study will include adult ICU patients (> 14 years old) admitted to KFSHRC ICUs within the previous 24 hours, placed on the ventilator, expected to need breathing tube for longer than 24 hours and placed on KFSHRC sedation and pain protocol. Patients will be separated to 2 groups: The intervention group: will receive a low dose ketamine infusion used in combination of standard of care. Ketamine will be given as intravenous infusion at a fixed infusion rate 0.12 mg/kg/hr (2 µg/kg/min) in 1st 24hr followed by 0.06 mg/kg/hr (1 µg/kg/min) in 2nd 24hr. The control group which will receive standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC ICU sedation and analgesia protocol as chosen by the treating clinician.The randomization process is computer-generated using block randomization with a size of 8 patients in each block.

The number of the subjects to be enrolled in this study is 80 and duration of the subject's participation is 48hrs. Patients will be assessed for duration of mechanical ventilation as a primary outcome.

Study medication (i.e. ketamine) will be administered until one the following occurs:

• Patient has received ketamine for 48 hours (intended duration if the study), or
• If ICU team deemed excessive sedation persisted after holding or decreasing the sedating medication and patient not on target sedation score called RASS,
• Patient died or goal of care changed to comfort care
• Patient extubated and sedation weaned off ,
• an adverse event potentially attributable to the study drug is experienced by a patient that is deemed, in the opinion of the investigative team to warrant discontinuation of therapy such as fast heart beat persist >150 beat per min for more than 3 hours, high systolic blood pressure persist > 180 for more than 3 hours, severe agitation and pulling off breathing tube or lines, and aggressive behavior to the nursing staff.

Inclusion criteria

• Adult ICU (Medical or surgical) patients (> 14 years old)
• Mechanically ventilated within the previous 24 hours and expected to remain intubated for more than 24 hours.
• The patient requires ongoing sedative medication
• No objection from the ICU attending MD for enrollment

Exclusion criteria

• Patients with a history of dementia or psychiatric disorders or on any anti-psychotics or anti-depressants medications at home
• Pregnancy
• Age < 14 years old
• Expected to need mechanical ventilation less than 24 hours
• Known hypersensitivity to ketamine
• Patient on dexmedetomidine as primary sedative agent prior to randomization
• Patients with cardiogenic shock, heart failure, myocardial infarction
• History of end-stage liver disease.
• Proven or suspected primary neurological injury (traumatic brain injury, ischemic stroke, intracranial hemorrhage, spinal cord injury, anoxic brain injury)
• Patients with persistent heart rate (HR) > 150 bpm or systolic blood pressure (SBP) >180 mmHg
• Patients who assigned as do-not-resuscitate order (DNR) or expected to die within 24 hours
• Patients on ECMO
• Patients with status epilepticus patients who are receiving the ketamine infusion for refractory status epilepticus
• Proven or suspected status asthmaticus
• Patients with expected targeted RASS of -5 such as patients on continuous infusion neuromuscular blockade